- Home
- VRCA vs AVTX Comparison
VRCA vs AVTX Comparison
Compare VRCA & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- AVTX
- Stock Information
- Founded
- VRCA 2013
- AVTX 2011
- Country
- VRCA United States
- AVTX United States
- Employees
- VRCA N/A
- AVTX N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- VRCA Health Care
- AVTX Health Care
- Exchange
- VRCA Nasdaq
- AVTX Nasdaq
- Market Cap
- VRCA 54.0M
- AVTX 57.4M
- IPO Year
- VRCA 2018
- AVTX 2015
- Fundamental
- Price
- VRCA $0.82
- AVTX $4.88
- Analyst Decision
- VRCA Hold
- AVTX Strong Buy
- Analyst Count
- VRCA 5
- AVTX 7
- Target Price
- VRCA $6.00
- AVTX $31.00
- AVG Volume (30 Days)
- VRCA 745.9K
- AVTX 88.6K
- Earning Date
- VRCA 08-13-2025
- AVTX 08-11-2025
- Dividend Yield
- VRCA N/A
- AVTX N/A
- EPS Growth
- VRCA N/A
- AVTX N/A
- EPS
- VRCA N/A
- AVTX N/A
- Revenue
- VRCA $7,179,000.00
- AVTX $441,000.00
- Revenue This Year
- VRCA $171.87
- AVTX N/A
- Revenue Next Year
- VRCA $71.38
- AVTX N/A
- P/E Ratio
- VRCA N/A
- AVTX N/A
- Revenue Growth
- VRCA N/A
- AVTX N/A
- 52 Week Low
- VRCA $0.38
- AVTX $3.39
- 52 Week High
- VRCA $8.98
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- VRCA 68.47
- AVTX 56.99
- Support Level
- VRCA $0.52
- AVTX $4.63
- Resistance Level
- VRCA $0.67
- AVTX $4.99
- Average True Range (ATR)
- VRCA 0.08
- AVTX 0.28
- MACD
- VRCA 0.03
- AVTX 0.01
- Stochastic Oscillator
- VRCA 70.47
- AVTX 87.64
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).